Literature DB >> 22112468

The biology of incipient, pre-invasive or intraepithelial neoplasia.

William E Grizzle1, Sudhir Srivastava, Upender Manne.   

Abstract

Invasive tumors (cancers or malignant lesions) typically develop in the setting in which there is the presence of putative non-invasive lesions and the development of these non-invasive lesions frequently precedes the development of cancers. For some organs, such as the oral cavity, cervix and skin, the respective putative pre-invasive lesions can be observed over time and documented to progress to invasive lesions. However, for less readily observable lesions, such as those of the prostate, the progression of the pre-invasive lesions, e.g., prostatic intraepithelial neoplasia (PIN) and prostatic proliferative inflammatory atrophy (PIA) to prostatic cancer are more difficult to document. Thus, for most organ systems, specific pre-invasive neoplastic lesions have been proposed based upon the apparent observations of one or more of the following: 1) microinvasive disease developing from a pre-invasive neoplastic lesion, 2) the general association of the pre-invasive lesion with invasive lesions, 3) the subsequent development of invasive lesions following diagnosis of the pre-invasive lesion, 4) correlations of the molecular features of the putative pre-invasive lesion with the matching invasive lesions, and 5) reductions in the rate of cancer following removal of the pre-invasive lesion. When there are mixtures of pre-invasive lesions with actual cancers in the same case, some of the above specific associations are more difficult to make. Several terms have been used to describe pre-invasive lesions, many of which are now less useful as our knowledge of these lesions increases. It is now commonly accepted that these lesions are a features of the spectrum of neoplastic development and most are accepted as ``neoplastic lesions'' with associated molecular features, even though they may be reversible even if they have mutations in suppressor genes (e.g., p53) or are associated with viral etiologies (e.g., cervical intraepithelial neoplasia). The overall term, "pre-invasive neoplasia", seems to best describe these putative pre-invasive lesions. Thus, terms such as incipient neoplasia should be abandoned. The term "intra-epithelial neoplasia" with an associated grade, which has been developed for pre-invasive neoplastic lesions of the cervix, i.e. cervical intraepithelial neoplasia (CIN), seems to be a terminology that adds consistency across epithelial organs. Thus, adoption of these terms for the additional organ sites of pancreas (PanIN) and prostate (PIN) seems accepted. Less descriptive terms such as the degrees of dysplasia of the oral cavity and bronchopulmonary system and actinic keratosis and Bowen's disease of the skin might be better designated as oral intraepithelial neoplasia (OIN), pulmonary intraepithelial neoplasia (PulIN) and dermal intraepithelial neoplasia (DIN). The etiology of pre-invasive neoplasia is the etiology of the matching cancers. Some obvious initiating factors include exposure to the whole range of ionizing and non-ionizing radiation, tobacco abuse and a broad range of other carcinogens (e.g., benzene). A frequent initiation factor is the setting of long standing continuing damage, inflammation and repair (LOCDIR) which leads to early molecular features associated with neoplasia after about one year. An excellent example of this is ulcerative colitis (UC) in which dysregulation of microsatellite repair enzymes have been documented one year following diagnosis of UC. While the nomenclature, description, diagnosis and etiology of pre-invasive neoplasia has advanced, approaches to therapy of such lesions have not progressed adequately even though it has been identified that, for example, removal of polyps periodically from the colorectum, DCIS from the breast, and high grade CIN from the cervix, results in a reduction in the development of cancers of the colorectum, breast, and cervix, respectively. With the development of more molecularly targeted therapy with fewer side effects, preventive therapies may be more successfully targeted to pre-invasive neoplastic lesions.

Entities:  

Mesh:

Year:  2010        PMID: 22112468      PMCID: PMC3430522          DOI: 10.3233/CBM-2011-0172

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  65 in total

1.  Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry.

Authors:  A Clayton; J Court; H Navabi; M Adams; M D Mason; J A Hobot; G R Newman; B Jasani
Journal:  J Immunol Methods       Date:  2001-01-01       Impact factor: 2.303

Review 2.  A mutator phenotype in cancer.

Authors:  L A Loeb
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

3.  Induction of myeloid-derived suppressor cells by tumor exosomes.

Authors:  Xiaoyu Xiang; Anton Poliakov; Cunren Liu; Yuelong Liu; Zhong-bin Deng; Jianhua Wang; Ziqiang Cheng; Spandan V Shah; Gui-Jun Wang; Liming Zhang; William E Grizzle; Jim Mobley; Huang-Ge Zhang
Journal:  Int J Cancer       Date:  2009-06-01       Impact factor: 7.396

4.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

5.  p53 Nuclear accumulation and Bcl-2 expression in contiguous adenomatous components of colorectal adenocarcinomas predict aggressive tumor behavior.

Authors:  Chandrakumar Shanmugam; Venkat R Katkoori; Nirag C Jhala; William E Grizzle; Gene P Siegal; Upender Manne
Journal:  J Histochem Cytochem       Date:  2007-12-10       Impact factor: 2.479

Review 6.  Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy.

Authors:  Madhuri Kakarala; Max S Wicha
Journal:  J Clin Oncol       Date:  2008-06-10       Impact factor: 44.544

7.  Reticulocyte-secreted exosomes bind natural IgM antibodies: involvement of a ROS-activatable endosomal phospholipase iPLA2.

Authors:  Lionel Blanc; Céline Barres; Pascale Bette-Bobillo; Michel Vidal
Journal:  Blood       Date:  2007-07-31       Impact factor: 22.113

8.  Thymus exosomes-like particles induce regulatory T cells.

Authors:  Gui-Jun Wang; Yuelong Liu; Aijian Qin; Spandan V Shah; Zhong-bin Deng; Xiaoyu Xiang; Ziqiang Cheng; Cunren Liu; Jianhua Wang; Liming Zhang; William E Grizzle; Huang-Ge Zhang
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

9.  Intraductal carcinoma of the breast: follow-up after biopsy only.

Authors:  D L Page; W D Dupont; L W Rogers; M Landenberger
Journal:  Cancer       Date:  1982-02-15       Impact factor: 6.860

10.  Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells.

Authors:  Kenyon G Daniel; Di Chen; Shirley Orlu; Qiuzhi Cindy Cui; Fred R Miller; Q Ping Dou
Journal:  Breast Cancer Res       Date:  2005-09-20       Impact factor: 6.466

View more
  11 in total

1.  A quantitative diagnostic method for oral mucous precancerosis by Rose Bengal fluorescence spectroscopy.

Authors:  Lei Zhang; Liangjia Bi; Jinna Shi; Zhiguo Zhang; Wenwu Cao; Jiang Lin; Chengzhang Li; Jiarui Bi; Yang Yu
Journal:  Lasers Med Sci       Date:  2012-05-31       Impact factor: 3.161

2.  Use of human specimens in research: the evolving United States regulatory, policy, and scientific landscape.

Authors:  Marianna J Bledsoe; William E Grizzle
Journal:  Diagn Histopathol (Oxf)       Date:  2013-09

Review 3.  Biomarkers and the genetics of early neoplastic lesions.

Authors:  Sudhir Srivastava; William E Grizzle
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

4.  Translational pathology of neoplasia.

Authors:  William E Grizzle; Sudhir Srivastava; Upender Manne
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

Review 5.  Development and progression of colorectal neoplasia.

Authors:  Upender Manne; Chandrakumar Shanmugam; Venkat R Katkoori; Harvey L Bumpers; William E Grizzle
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

6.  Risk Stratification System for Oral Cancer Screening.

Authors:  Lutécia H Mateus Pereira; Isildinha M Reis; Erika P Reategui; Claudia Gordon; Sandra Saint-Victor; Robert Duncan; Carmen Gomez; Stephanie Bayers; Penelope Fisher; Aymee Perez; W Jarrard Goodwin; Jennifer J Hu; Elizabeth J Franzmann
Journal:  Cancer Prev Res (Phila)       Date:  2016-03-28

7.  Opportunities for molecular epidemiological research on ductal carcinoma in-situ and breast carcinogenesis: interdisciplinary approaches.

Authors:  Mark E Sherman; Carolyn Mies; Gretchen L Gierach
Journal:  Breast Dis       Date:  2014

8.  Potential therapeutic effect of the secretome from human uterine cervical stem cells against both cancer and stromal cells compared with adipose tissue stem cells.

Authors:  Noemí Eiró; Juan Sendon-Lago; Samuel Seoane; María A Bermúdez; Maria Luz Lamelas; Tomás Garcia-Caballero; José Schneider; Roman Perez-Fernandez; Francisco J Vizoso
Journal:  Oncotarget       Date:  2014-11-15

9.  Polyomavirus BK and prostate cancer: an unworthy scientific effort?

Authors:  Pasquale Ferrante; Maurizio Provenzano; Serena Delbue
Journal:  Oncoscience       Date:  2014-04-30

10.  Expression of aldehyde dehydrogenase after neoadjuvant chemotherapy is associated with expression of hypoxia-inducible factors 1 and 2 alpha and predicts prognosis in locally advanced breast cancer.

Authors:  Daniel Guimarães Tiezzi; Willian Simões Clagnan; Larissa Raquel Mouro Mandarano; Christiani Bisinoto de Sousa; Heitor Ricardo Cosiski Marana; Marcelo Guimarães Tiezzi; Jurandyr Moreira de Andrade
Journal:  Clinics (Sao Paulo)       Date:  2013-05       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.